Posted by Michael Wonder on 19 Feb 2025
Durvalumab in combination with etoposide phosphate and either carboplatin or cisplatin for the first-line treatment of patients with extensive-stage small-cell lung cancer
19 February 2025 - NICE has published final evidence-based recommendations on the use of durvalumab (Imfinzi) in combination with etoposide phosphate and either carboplatin or cisplatin for adults with untreated extensive-stage small-cell lung cancer.
Durvalumab, when used with etoposide phosphate and either carboplatin or cisplatin, is recommended as an option for the first-line treatment of adults with extensive-stage small-cell lung cancer only if they have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and AstraZeneca provides durvalumab according to the commercial arrangement.
